Name

Vesalio

Legal name

Vesalio

Website

https://vesalio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neurovascular Thrombectomy Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industries

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Stroke & Vascular Neurology (HLAKAIAG)

Keywords

• Thrombectomy devices
• Mechanical thrombectomy
• Neurovascular stents
• Stroke treatment devices
• Vascular occlusion devices

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Vesalio generates revenue through the sale of its proprietary thrombectomy devices including NeVa (neurovascular), enVast (coronary), and pVasc (peripheral). The company operates through direct sales teams in the U.S. and a network of exclusive distribution partners internationally. Products are sold to hospitals and medical centers for use in interventional procedures.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Vesalio develops, manufactures, and commercializes proprietary mechanical thrombectomy devices for the treatment of vascular occlusions across neurovascular, coronary, and peripheral circulations. Its flagship products include NeVa (stroke thrombectomy), NeVa NET (stent retriever with integrated micro-filter), NeVa VS (post-aSAH cerebral vasospasm), enVast (coronary large thrombus burden), and pVasc (peripheral arterial occlusion). All products are built on the patented Drop Zone™ technology platform and are sold to hospitals and interventional specialists.

Product overview

Vesalio is a medical device company offering a comprehensive thrombectomy platform with multiple specialized products targeting different vascular territories. The portfolio includes NeVa (neurothrombectomy for stroke), NeVa NET (with integrated distal micro-filter for embolic protection), NeVa VS (for cerebral vasospasm treatment), enVast (coronary thrombectomy), pVasc (peripheral vascular thrombectomy), and NeVaSC (aspiration catheters). All products share Vesalio's proprietary Drop Zone technology designed to capture and retain clots across the entire vasculature.

Differentiator

Problem solved

Functional benefit

Brands

• NeVa: Neurothrombectomy platform for acute ischemic stroke treatment featuring Drop Zone technology for first-pass success with all clot types.
• NeVa NET
• NeVa VS
• enVast
• pVasc

Products and services

• NeVa Neurothrombectomy System Multifunctional stent retriever neurothrombectomy device designed for first-pass success with all clot types in acute ischemic stroke treatment. Uses proprietary Drop Zone™ technology with multiple integrated capture zones to trap and retain thrombus. Available in multiple sizes including 3.0mm and 5.5mm diameters with varying Drop Zone configurations. Intended for hospitals and stroke centers performing endovascular procedures.
• NeVa NET (with Micro-Filter) Stent retriever with the world's first and only micro-filter integrated in the distal tip, designed to maximize clot retention and prevent distal embolization during thrombectomy. Available in 4.0mm and 5.5mm sizes. Targets neurointerventionalists performing acute ischemic stroke procedures in hospitals and stroke centers.
• NeVa VS (Vasospasm Stent) FDA-approved retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). Features smooth continuous architecture with enhanced outward radial force to dilate critically narrowed vessels. The only FDA-approved device for this indication. Targets neurosurgeons and neurointerventionalists at academic neuroscience centers.
• enVast Coronary Thrombectomy Device Stent-based coronary thrombectomy device employing Drop Zone™ technology adapted for cardiac circulation to facilitate flow restoration in patients with large thrombus burden during primary PCI. First and only CE-approved and FDA-cleared large thrombus burden retriever for coronary arterial occlusion. Targets interventional cardiologists and PCI centers treating STEMI patients.
• pVasc Peripheral Thrombectomy System Mechanical thrombectomy system for peripheral arterial occlusion. Comprised of a self-expanding nitinol structure on a pusher wire designed for low profile and excellent deliverability in difficult peripheral anatomy. Indicated for non-surgical removal of occlusions from peripheral vasculature (arteries 2–6 mm in diameter). Targets vascular surgeons and interventional radiologists treating acute limb ischemia.
• NeVaSC Aspiration Catheter Aspiration catheter for neurovascular and peripheral applications, with expanded indications for distal access with microcatheter delivery. Targets interventional neuroradiologists, neurointerventionalists, and vascular specialists performing thrombectomy procedures.

Quantifiable outcome

• 90.7% substantial reperfusion within three passes (97/107 patients) in CLEAR study
• +6 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core.

• J.D. McCullochcoreOthersJ.D. McCulloch serves as Chief Financial Officer overseeing all financial aspects of the business including finance, strategic planning and budgeting, cash management, and risk management. Brings over 25 years of professional experience spanning investment management, investment banking, business valuation, and corporate finance with focus on healthcare and biotech over the last decade.
• Bob BushokcoreOthersBob Bushok serves as VP of U.S. Sales, leading the commercial expansion in the United States market. Previously appointed to build and manage the U.S. sales team in conjunction with NeVa VS product launch.
• Gustavo PradocoreOthersGustavo Prado serves as VP of Development and Operations, overseeing product development and operational activities. Commented on publications regarding NET micro-filtration technology.
• Vassa MedicalcoreChannel Partner/ Reseller/ DistributorExclusive distribution partner for Italy. National sales network trained and celebrating NeVa launch at company headquarters in Mirano near Venice. Dr. Massimo Sponza from Udine Hospital trained the team on acute ischemic stroke and thrombectomy.
• Vall d'Hebron Research InstitutecoreStrategic or Co-development PartnerBarcelona-based research institute that hosted Vesalio Clot Interaction Workshops where physicians from 8 different countries trained on NeVa Drop Zone Retrieval Technique. Used proprietary flow model for training sessions.
• Akpinar et al.coreStrategic or Co-development PartnerResearch collaboration resulting in publication in Interventional Neuroradiology reporting remarkable first-pass recanalization rates in multi-center, real-life setting study of NeVa.
• BMJ (British Medical Journal)coreStrategic or Co-development PartnerPublished primary results from CLEAR study evaluating NeVa stent retriever for mechanical thrombectomy in acute ischemic stroke - a prospective multicenter FDA-regulated trial.
• VITAL Study InvestigatorscoreStrategic or Co-development PartnerClinical research collaboration resulting in publication in Journal of NeuroInterventional Surgery of VITAL trial demonstrating safety and efficacy of NeVa VS for treatment of symptomatic cerebral vasospasm following aSAH.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Inari Medical: Inari Medical develops mechanical thrombectomy devices for venous thromboembolism and peripheral arterial disease (FlowTriever, ClotTriever), directly comparable to Vesalio's pVasc in the peripheral vascular space.
• Penumbra: Penumbra is a leading thrombectomy company with both neurovascular (Penumbra System, RED reperfusion catheters) and peripheral vascular product lines, making it the closest direct competitor across Vesalio's full neurovascular and peripheral vascular portfolio.
• AngioDynamics: AngioDynamics offers mechanical thrombectomy and peripheral vascular products (e.g., AlphaVac, Auryon) that overlap with Vesalio's pVasc peripheral system and aspiration catheter portfolio.

Broad incumbents

• Medtronic: Medtronic's Solitaire stent retriever is a market-leading mechanical thrombectomy device for acute ischemic stroke. Medtronic also competes in peripheral and coronary vascular intervention, making it a broad incumbent across Vesalio's product territories.
• Stryker (Neurovascular): Stryker's Neurovascular division operates the Trevo stent retriever, one of the dominant devices in mechanical thrombectomy for acute ischemic stroke. As a large incumbent with a broad hospital footprint, Stryker competes directly with NeVa while also offering wider neurovascular portfolios.
• Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular business, offers the Embotrap stent retriever and other thrombectomy devices directly competing with Vesalio's NeVa platform in acute ischemic stroke.
• Terumo (Neurovascular): Terumo's neurovascular business offers access and aspiration products that intersect with Vesalio's aspiration catheter portfolio and broader neurovascular platform.

Emerging players

• Balt: Balt is a neurovascular-focused medical device company offering access catheters, coils, and thrombectomy-related products that compete with Vesalio's neurovascular portfolio in Europe and other markets.
• Rapid Medical: Rapid Medical develops neurovascular devices including the Tigertriever stent retriever, a competitor in the mechanical thrombectomy space targeting similar acute ischemic stroke indications as Vesalio's NeVa.
• Acandis: Acandis develops stent-based devices for neurovascular applications including thrombectomy and aneurysm treatment, partially overlapping with Vesalio's NeVa platform in stroke intervention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vesalio_neva
• LinkedInlinkedin.com/company/vesalio
• Facebookfacebook.com/Vesalio-1878291765747392

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesalio